GCC2005 + cyclophosphamide + fludarabine

**GCC2005 + cyclophosphamide + fludarabine** is an experimental combination therapy under investigation for the treatment of relapsed or refractory natural killer (NK)/T-cell malignancies. GCC2005 is an investigational agent; while specific molecular details about GCC2005 are limited in the public domain as of 2024, it is being studied alongside the established chemotherapeutic agents cyclophosphamide and fludarabine in a Phase 1 clinical trial. Cyclophosphamide is an alkylating agent that crosslinks DNA and suppresses both immune and malignant cell function; fludarabine is a purine analog antimetabolite that inhibits DNA synthesis. This regimen is designed to leverage the cytotoxic and immunosuppressive properties of these drugs, potentially in preparation for cell therapies or to enhance antitumor efficacy in hematologic cancers[9][2][4][8].